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One explanation for the clinical association between tumour vascularity and probability of metastasis is that increased primary
tumour vascularity enhances haematogenous dissemination by offering greater opportunity for tumour cell invasion into the
circulation (intravasation). We devised an experimental tumour metastasis model that allowed manipulation of primary tumour
vascularity with differential exposure of the primary and metastatic tumour site to angiogenic agents. We used this model to
assess the effects of local and systemic increases in the level of the angiogenic agent basic fibroblast growth factor on
metastasis. BDIX rats with implanted hind limb K12/TR adenocarcinoma tumours received either intratumoural or systemic,
basic fibroblast growth factor or saline infusion. Both intratumoural and systemic basic fibroblast growth factor infusion
resulted in significant increases in tumour vascularity, blood flow and growth, but not lung metastasis, compared with saline-
infused controls. Raised basic fibroblast growth factor levels and increase in primary tumour vascularity did not increase
metastasis. The clinical association between tumour vascularity and metastasis is most likely to arise from a metastatic tumour
genotype that links increased tumour vascularity with greater metastatic potential.
British Journal of Cancer (2002) 86, 123 – 129. DOI: 10.1038/sj/bjc/6600020 www.bjcancer.com
ª 2002 The Cancer Research Campaign
Keywords: tumour vascularity; metastasis; angiogenesis; basic fibroblast growth factor
Clinical studies of breast, lung, cervical and colorectal cancer
suggest that tumour vascularity is related to risk of metastasis
(Matsuyama et al, 1998; Nanashima et al, 1998; Tjalma et al,
1998; Weidner, 1998). One causal explanation is that increased
vascularity within the primary tumour may offer greater opportu-
nity for tumour cell invasion into the circulation, resulting in
enhanced haematogenous dissemination.
In support of this, a relationship between tumour vascularity
and the number of circulating tumour cells (CTC) has been
demonstrated in an animal tumour model (Liotta et al, 1974).
However, more recent clinical studies suggest that CTC’s are
frequently detected in patients with invasive cancer, regardless of
tumour vascularity, stage or clinical outcome (Ennis et al, 1997;
Wharton et al, 1999; Mathur et al, 2001). Metastasis involves addi-
tional critical steps – including attachment to vascular
endothelium, and extravasation (Fidler, 1997) – and the relation-
ship between primary tumour vascularity and metastasis could
derive from oncogene mutations that – as in the case of k-ras
or p53 – influence vascular (Rak et al, 1995; Mehta et al, 2001)
as well as tumour metastatic (Bartsch et al, 1998; Maehara et al,
2000) phenotype.
We developed an experimental tumour metastasis model that
allowed differential exposure of the primary and metastatic tumour
site to the angiogenic agent basic fibroblast growth factor (bFGF),
in order to vary primary tumour vascularity without altering
tumour genotype. We assessed the effects of variation in tumour
vascularity by both local and systemically administered bFGF, on
tumour metastasis.
METHODS
K12/TR tumour cell line
The K12/TR cell line (courtesy Dr S Watson, Queen’s Medical
Centre, Nottingham, UK and Dr S Eccles, Institute of Cancer
Research, Sutton, UK) is a transplantable hypovascular rat colonic
adenocarcinoma that metastasises to the lungs from the subcuta-
neous implantation site (Dunnington et al, 1987).
In vitro K12/TR cell line proliferation in response to bFGF
K12/TR cells suspended in 100 ml DMEM medium were added to 96-
well plates, and then incubated overnight at 378C in 5% CO2. The
medium was removed and replaced by bFGF diluted in DMEM.
Previous in vitro studies have demonstrated that a bFGF concentra-
tion of 3 ng ml71 induces cell proliferation (Montesano et al,
1986). Three bFGF concentrations (3 ng ml71, 30 ng ml71,
150 ng ml71) and a negative (saline) control, were used. The cells
were incubated for a further 4 days, and an MTT (3-(4,5-
dimethylthiazol)-2,5-diphenyltetrazolium bromide) assay then used
to quantify cell number. MTT is a soluble tetrazolium salt that is
converted by viable cells to an insoluble formazan precipitate
(Mosmann et al, 1983) that forms a purple coloured solution when
dissolved in an organic solvent. The optical density of the solution
is proportional to the number of viable cells (Carmichael et al,
1987). 0.1 mg of MTT in 200 ml of PBS was added to each well of
the plate which was then incubated at 378C for 4 h. The medium
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was then aspirated leaving a formazan crystal residue which was
dissolved by adding 200 ml of DMSO to each well and agitating for
10 min. The optical density of each well was read at 570 nm using
a spectrophotometer (Titertek Multiscan, Finland).
In vivo K12/TR tumour implantation
The K12/TR cell line was grown and prepared as previously
described (Dunnington et al, 1987). Male BDIX rats (median
weight, 403 g; (range 309 – 459)) were anaesthetized with a 1 –
2% mixture of Halothane and oxygen (May & Baker, UK) using
a commercial vaporizer (Halovet, IMS, UK). Subcutaneous flank
tumours were produced by injecting 0.1 mls phosphate buffered
saline containing 106 cells through a cannula placed subcutaneously
in the flank of each animal. The animals were then divided into
groups for either intratumoural or systemic infusion of either bFGF
or saline.
Osmotic infusion pump insertion and intratumoural bFGF
infusion
The flank tumour injection cannula was then connected to an Alzet
osmotic mini-pump (Charles River, Maidstone, UK) that was
placed in a subcutaneous pocket. The tumour cell inoculum was
then continuously infused at a 0.25 ml h71 with either bFGF or
saline (control group) for 28 days from the time of cell injection.
The bFGF was delivered at a dose rate of 100 ng per 24 h, as this
dose has previously been shown to stimulate angiogenesis in a rat
subcutaneous sponge model (Hu et al, 1994).
Osmotic infusion pump insertion and systemic bFGF
infusion
After flank tumour injection, the internal jugular vein was cannu-
lated and connected to an Alzet osmotic mini-pump (Charles
River, Maidstone, UK; 0.25 ml h71). bFGF was delivered at a dose
rate of 5 mg per 24 h. This dose has previously been demonstrated
to increase liver metastasis vascularity when infused systemically in
a rat fibrosarcoma model (Davies et al, 2001).
Flank tumour assessments
Flank tumour blood flow was assessed in non-recovery experi-
ments, after a 4-week tumour growth period (see below).
Blood flow The tissue equilibration method (Tozer and Shaffi,
1993) was used. After anaesthesia for flank tumour excision,
50 mCi of [I-125]-Iodoantipyrine ([I-125]-IAP) in 0.5 ml 0.9%
saline was infused over 30 s via a polythene cannula (ID
0.28 mm, Portex, UK) inserted into the internal jugular vein.
The infusion was stopped and the animal weighed and killed.
The flank tumours were excised, rapidly frozen (51 min) in a
pre-cooled isopentane freezing bath (7708C), and stored in liquid
nitrogen until assessed. Each subcutaneous tumour was bisected
and equatorial tissue sections were cut for blood flow (20 mm),
vascularity (6 mm) and cell proliferation (6 mm) assessments using
a cryostat (Bright Instruments, UK).
Tissue sections for autoradiography were transferred onto glass
slides and allowed to dry at room temperature. They were then placed
on b-max (Kodak, UK) autoradiography film with calibration stan-
dards and then exposed for 3 weeks. Autoradiographic images were
digitized for analysis using a PC based image processing system
(Microscale TC, Digithirst Ltd, UK), with a pixel resolution of
34638 mm. Line profiles were drawn from the tumour edge to the
tumour centre and the transmitted light intensity value of each pixel
on the profile was recorded. Each film was calibrated using co-
exposed I-125 standards and the light intensity values were converted
to (I-125)-IAP concentrations, and then normalized with respect to
the tumour edge. Between 6 – 8 line profiles drawn at intervals
around each tumour boundary were averaged per tumour. Tissue
concentration of (I-125)-IAP was used as a relative measure of blood
flow. We have previously found (unpublished observations) that
tissue blood flow is directly proportional to Iodoantipyrine concen-
tration up to flow rates (approximately 0.5 ml min g71) that
exceed those reported (Hemingway et al, 1991) in the hypovascular
tumours used in the present study.
Vascularity Six mm thick cryostat (Bright Instruments, UK)
sections were cut and fixed in acetone, and endogenous peroxidase
activity was then blocked with 0.1% Hydrogen Peroxide. After
washing in TRIS-buffered saline and blocking for non-specific
activity with diluted normal rabbit serum (Dako, UK.), sections
were incubated with monoclonal Ox-43 primary antibody (MCA
276, Serotec, UK) at a dilution of 1 : 300 for 30 min. Subsequent
processing was carried out using the streptavidin-biotin method
(Dako) after washing in TBS containing 1 ml 1% 10-ethyl ether.
The complex was visualized using diaminobenzydine and counter-
stained with Mayer’s Haemotoxylin. Positive and negative controls
were respectively, rat heart muscle, and flank tumour without
primary antibody exposure.
After staining, tumour sections were independently assessed for
vascularity by two of the authors (MM Davies and P Mathur) at
6400 magnification (Nikon Optiphot, 610 eye-piece, 640 objec-
tive) without knowledge of infusion group. Vessel volume fraction
was assessed by Chalkley’s method (Chalkley, 1943) using a 25 dot
eyepiece graticule. Vessel length density was assessed by counting
all stained features within a 245 mm6175 mm rectangular field
(Aherne and Dunnill, 1982). Forty fields were selected randomly
over the tumour section for each measurement. Distribution of
vascularity was assessed on line profiles of vessel length density
(Underwood, 1970), by counting vessels within adjacent fields
while moving from tumour periphery to centre. Between 6 – 8 such
line profiles were obtained and averaged for each tumour section.
Proliferation Proliferation was assessed by quantifying the
expression of the 36 kDa nuclear protein Proliferating Cell Nuclear
Antigen (PCNA). PCNA is an auxiliary protein for DNA polymer-
ase and it accumulates from stages G1 to M of the cell cycle, its
presence within a cell indicates that the cell is proliferating (Hall
et al, 1990). Detection of the PCNA protein can be achieved by
immunohistochemical staining of tumour sections with an anti-
PCNA monoclonal antibody (PC10, Dako, UK).
Contiguous 6 mm flank tumour sections were fixed in 4%
formalin for 2 min, then ethanol for a further 10 min and blocked
for endogenous peroxide activity with 0.1% Hydrogen Peroxide.
After washing in TRIS-buffered saline and blocking for non-specific
activity with diluted normal rabbit serum (Dako, UK), the sections
were incubated with the monoclonal primary anti-PCNA antibody
(PC10, Dako, UK) at a dilution of 1 : 100 for 30 min. The second-
ary and tertiary layers were applied as per the Dako streptavidin-
biotin complex after washing in TBS containing 1 ml 1% 10-ethyl
ether. The complex was visualized using diaminobenzydine and
counterstained with Mayer’s Haemotoxylin. Sections were exam-
ined at 6400 magnification using a Nikon (Optiphot)
microscope (610 eyepiece, 640 objective) with a 2456175 mm
rectangular field placed in the eyepiece. One thousand cells were
counted in eight randomly placed fields. All brown staining cells
were considered positive. PCNA was quantified by the PCNA index
which was defined as the percentage of positive staining cells per
1000 cells counted (Teixeira et al, 1994).
Growth Every 2 days after tumours became palpable (approxi-
mately 14 days after flank tumour injection), two perpendicular
(to a vertical axis through the approximate centre of the tumour)
measurements were made of the shortest and longest tumour
dimensions. A value for the volume of each tumour was then
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derived according to the formula: Vol=(p/6)6(a26b) (Euhus et
al, 1986).
Lung metastasis assessments
After a 4-week primary tumour growth period and a further 8
weeks following flank tumour excision (see above), animals were
killed, weighed and examined for lung metastases. Studies in mice
suggest that macroscopic examination of lungs for the presence of
metastases correlates closely with results of serial sectioning and
microscopic examination (Wexler, 1966). Macroscopic examination
of lungs was performed to assess the prevalence of metastasis. The
number of lung metastases per animal, and lung weight were also
assessed as additional indicators of extent of lung metastasis
(Kolber et al, 1995).
The lungs of each animal were excised and fixed in methacarn
(methanol-inhibisitol-acetic acid in the ratio 6 : 3 : 1) overnight
and then examined using a dissecting microscope (Nikon Opti-
phot, Japan; 610 eye-piece, 620 objective) for the presence of
metastases and weighed. Brain, intra-abdominal organs, and axil-
lary and inguinal lymph node groups were also macroscopically
examined for metastases.
Statistical methods and experimental guidelines
Differences between bFGF and saline infused groups were assessed
by Mann Whitney-U test. Repeated measures analysis of variance
was used to assess vessel length density and tumour:tumour edge
125I (blood flow) ratio differences from tumour edge to centre
between bFGF and saline infusion groups. Lung metastasis experi-
ments were designed to provide an 80% power of detecting as
significant (P50.05), a 50% increase in lung metastasis with the
bFGF-induced increase in flank tumour vascularity. This required
a total sample of 28 animals in each metastasis experiment.
All experiments using laboratory animals were carried out
according to UKCCCR guidelines and were approved under the
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Figure 1 There was a significant increase in proliferation rate of K12/TR
cells exposed to bFGF at a concentration of 3 ng ml71 (M.W.U. P=0.003)
and 30 ng ml71 (M.W.U. P=0.01) compared with the negative control.
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Figure 2 There were significant increases with distance from the tumour
edge in vessel length density (repeated measures analysis of variance,
P=0.0001) (above) and tumour to tumour edge blood flow ratio
(P=0.0005) (below) in bFGF infused subcutaneous K12/TR tumours com-
pared with controls (*: saline n=5;*: bFGF n=5; median and interquartile
range).
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Figure 3 There was a significant increase (M.W.U. P=0.03) in the PCNA
positive cell index (above) and in the tumour volume (M.W.U. P=0.05)
(below) of bFGF infused subcutaneous K12/TR tumours compared with
controls (*: saline n=5; *: bFGF n=5; median and interquartile range).
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terms of the UK Home Office Animals (Scientific Procedures) Act
1986. All laboratory animal procedures had also been reviewed by
the Royal Marsden Hospital Ethics Committee
RESULTS
In vitro K12/TR cell line proliferation in response to bFGF
There was a significant increase in the proliferation rate of K12/TR
cells exposed to bFGF at concentrations of 3 ng ml71 (median
200%, iqr 150 – 250%, P=0.003) and 30 ng ml71 (median 133%,
iqr 83 – 167%, P=0.01) compared with control (median 100%,
iqr 67 – 183%). Proliferation of cells exposed to bFGF at a concen-
tration of 150 ng ml71 (median 113%, iqr 93 – 130%) was not
significantly different (P=0.1) to control (Figure 1).
Intratumoural bFGF infusion into K12/TR flank tumours
Vascularity, blood flow, proliferation and growth Ten
tumours (five saline and five bFGF) from 10 animals were exam-
ined. There was no difference (P=0.3) in animal weights in bFGF
(371 g (362 – 421 g)) compared with saline (392 g (362 – 428 g))
groups.
There was a significant increase (P=0.008) in vessel length
density in the bFGF (median 65.3 mm mm73, iqr 61.8 –
77.0 mm mm73) compared with the saline (35.0 mm mm73,
33.8 – 35.6 mm mm73) groups. Similarly, there was a significant
increase (P=0.004) in vessel volume fraction in the bFGF (5.9%,
5.8 – 6.2%) compared with the saline (3.6%, 2.5 – 4.3%) group.
There was also a significant increase (P=0.0001) in vessel length
density with distance from the tumour edge between bFGF and
saline infused tumours (Figure 2). There was a significant increase
in tumour blood flow (P=0.0005) between bFGF infused compared
with saline-infused tumours (Figure 2).
There was a significant increase (P=0.03) in PCNA index in the
bFGF (median 20.5%, iqr 19.6 – 23.3%) compared with the saline
(11.5%, 9.4 – 14.9%) group. This was associated with a significant
increase (P=0.05) in the volume of bFGF compared with saline
infused tumours (Figure 3).
Lung metastasis Thirty-five animals were studied (saline n=17
and bFGF n=18). There was no significant difference in animal
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Figure 4 There was no significant difference (M.W.U. P=0.3) in the lung
weights of animals with bFGF infused primary K12/TR tumours compared
with controls (*: saline n=17; *: bFGF n=18; median and interquartile
range) (above). There was also no significant difference (M.W.U. P=0.3)
in the number of lung metastases per animal with bFGF infused primary
K12/TR tumours compared with controls (*: saline n=17; *: bFGF
n=18; median and interquartile range) (below).
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Figure 5 There were significant increases with distance from the tumour
edge in vessel length density (repeated measures analysis of variance,
P=0.0001) (above) and tumour to tumour edge blood flow ratio
(P=0.0001) (below) in subcutaneous K12/TR tumours infused systemically
with bFGF compared with controls (*: saline n=5; *: bFGF n=5; median
and interquartile range).
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weights (P=0.2) between bFGF (421 g (309 – 432 g)) and saline
groups. There was also no significant difference in lung weight
(P=0.3, Figure 4) or in number of lung metastases per animal
(P=0.3, Figure 4) between bFGF and saline infused groups. Grossly
enlarged ipsilateral axillary lymph nodes were identified in three
(two bFGF infused and one saline infused) of the 35 animals
studied. Metastases were not identified in other organs.
Systemic bFGF infusion in animals bearing K12/TR flank
tumours
Vascularity, blood flow, proliferation and growth Ten
tumours (five saline and five bFGF) from 10 animals were exam-
ined. There was no significant difference (P=0.4) in animal
weights between bFGF (329 g (309 – 421 g)) and saline (319 g
(298 – 398 g)) groups.
There was a significant increase (P=0.009) in vessel length
density in the bFGF (median 36.2 mm mm73, iqr 30.8 –
56.2 mm mm73) compared with the saline-infused
(10.6 mm mm73, 9.8 – 20.0 mm mm73) group. Similarly, there
was a significant increase (P=0.009) in vessel volume fraction in
the bFGF (6.4%, 5.5 – 7.3%) compared with the saline-infused
(1.8%, 1.3 – 2.0%) group. There was a significant increase
(P50.0001) in vessel length density with distance from the tumour
edge between bFGF and saline-infused tumours (Figure 5). There
was also a significant increase in tumour blood flow (P50.0001)
with distance from the tumour edge between bFGF and saline-
infused tumours (Figure 5).
There was a significant increase in PCNA index (P=0.04) in
the bFGF (median 13.6%, iqr 10.4 – 16.0%) compared with the
saline-infused (5%, 4.0 – 6.0%) group. There was a trend that
did not reach statistical significance (P=0.08), for an increase
in tumour volume of bFGF compared with saline-infused
tumours (Figure 6).
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Figure 6 There was a significant increase (M.W.U. P=0.04) in the PCNA
index in subcutaneous K12/TR tumours infused systemically with bFGF
compared with controls (*: saline n=5; *: bFGF n=5; median and inter-
quartile range) (above). There was no significant increase (M.W.U. P=0.08)
in the tumour volume of systemic bFGF infused subcutaneous K12/TR tu-
mours compared with controls (*: saline n=5; *: bFGF n=5; median and
interquartile range) (below).
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Figure 7 There was no significant difference (M.W.U. P=0.2) in the lung
weights of animals with primary K12/TR tumours infused systemically with
bFGF compared with controls (*: saline n=13; *: bFGF n=15; median
and interquartile range) (above). There was no significant difference
(M.W.U. P=0.9) in the number of lung metastases per animal with primary
K12/TR tumours infused systemically with bFGF compared with controls
(*: saline n=13; *: bFGF n=15; median and interquartile range) (below).
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Lung metastasis Twenty-eight animals were studied (systemic
saline infusion n=13, and systemic bFGF n=15). There was no
significant difference (P=0.4) in animal weights between bFGF
(421 g (313 – 439 g)) and saline (413 g (304 – 459 g)) groups. There
was also no significant difference in lung weight (P=0.2, Figure 7),
or in number of lung metastases per animal (P=0.9, Figure 7) in
bFGF compared with saline-infused groups. Enlarged ipsilateral
axillary lymph nodes were identified in five (three bFGF infused
and two saline infused) animals. Metastases were not detected in
other organs.
DISCUSSION
The finding that bFGF increased in vitro K12/TR adenocarcinoma
proliferation suggests that K12/TR proliferation was sensitive to
bFGF. This is likely to have been mediated by bFGF receptors that
have been described on the cell surface of some colonic adenocar-
cinomas (Terayama et al, 1996). This was consistent with the
significant in vivo increases in flank tumour proliferation and
growth that occurred with bFGF infusion.
Intratumoural and systemic bFGF infusion increase tumour
vascularity and blood flow in both the HSN sarcoma and the
K12/TR adenocarcinoma cell lines (Davies et al, 2001). Since the
HSN cell line does not proliferate in response to in vitro bFGF
or grow more rapidly in vivo on exposure to bFGF (Mathur et
al, 1999), it is most likely that the bFGF-related tumour vascularity
response was independent of tumour type – for example deriving
from a bFGF effect on host endothelial cells. This supports the
hypothesis that endothelial cells and tumour cells are separate
tumour components that can be individually manipulated (Folk-
man, 1996).
Interstitial bFGF infusion approximately doubled K12/TR flank
tumour vascularity, blood flow, proliferation and growth. These
increases were compatible with the primary tumour vascularity
increases that have been clinically associated with an increased risk
of metastasis (Weidner et al, 1991; 1993). It was unlikely that bFGF
administered into the interstitial space around the flank tumour
reached the lung metastatic site. The absence of a detectable
increase in lung metastasis suggested that these changes in flank
tumour vascularity and blood flow did not produce a 50% increase
in lung metastasis.
Systemic bFGF infusion produced increases in flank tumour
vascularity, blood flow and growth that were of a similar magni-
tude to those achieved with interstitial infusion of a 50-fold
smaller bFGF dose. Thus systemically-administered bFGF was
active at the flank tumour site. Despite systemic bFGF levels that
were capable of increasing flank tumour vascularity and can be
expected also to have reached the lungs, there was no significant
increase in lung metastasis.
These results do not support a role for raised levels of bFGF at
either the primary or metastatic tumour site, or for associated
increases in flank tumour vascularity and blood flow, in increasing
metastasis. Even if increased primary tumour vascularity increased
vascular intravasation (Liotta et al, 1974) – which is controversial
(Ennis et al, 1997; Wharton et al, 1999; Mathur et al, 2001) –
metastasis also involves additional critical steps – including attach-
ment to vascular endothelium, and extravasation (Fidler, 1997).
These steps may also have to be up-regulated to enhance tumour
metastatic phenotype. The results were consistent with the clinical
association between tumour vascularity and metastasis arising as
consequences of a tumour genotype – for example a k-ras or
p53 (Rak et al, 1995; Bartsch et al, 1998; Maehara et al, 2000;
Mehta et al, 2001) mutation – that associated increased tumour
vascularity with metastatic phenotype.
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